

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/764,728
Filing Date	January 26, 2004
First Named Inventor	Q. Ping Dou
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	USF-T195XC1

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AO	R1	CHEN, C. <i>et al.</i> "Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death" <i>Arch. Pharm. Res.</i> , 2000, 23(6):605-612.	
AO	R2	CHUNG, J.Y. <i>et al.</i> "Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3'-digallate" <i>FASEB J.</i> , 2001, 15:2022-2024.	
AO	R3	MASUDA, M. <i>et al.</i> "Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines" <i>Clin. Cancer Res.</i> , 2001, 7:4220-4229.	
AO	R4	YANG, C.S. and WANG, Z-Y "Tea and Cancer" <i>J. Natl. Cancer Inst.</i> , 1993, 85(13):1038-1049.	
AO	R5	YU, R. <i>et al.</i> "Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the regulation of antioxidant-responsive element-mediated Phase II enzyme gene expression" <i>Carcinogenesis</i> , 1997, 18(2):451-456.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner
Signature

/Amelia Owens/

Date

Considered


02/27/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/764,728
		Filing Date	January 26, 2004
		First Named Inventor	Q. Ping Dou
		Group Art Unit	1614
Examiner Name			
Attorney Docket Number	USF-T195XC1		
Sheet	1	of	1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AO	R1	KAZI, A. <i>et al.</i> "Inhibition of Bcl-X _L phosphorylation by tea polyphenols or epigallocatechin-3-gallate is associated with prostate cancer cell apoptosis" <i>Mol. Pharmacology</i> , 2002, 62(4):765-771.	
AO	R2	KAZI, A. <i>et al.</i> "Potential molecular targets of tea polyphenols in human tumor cells: significance in cancer prevention" <i>In Vivo</i> , 2002, 16(6):397-403.	
AO	R3	SMITH, D.M. <i>et al.</i> "Docking studies and model development of tea polyphenol proteasome inhibitors: Applications to rational drug design" <i>Proteins</i> , 2004, 54:58-70.	
AO	R4	SMITH, D.M. <i>et al.</i> "Synthetic analogs of green tea polyphenols as proteasome inhibitors" <i>Mol. Med.</i> , 2002, 8(7):382-392.	
AO	R5	SMITH, D.M. and DOU, Q.P. "Green tea polyphenol epigallocatechin inhibits DNA replication and consequently induces leukemia cell apoptosis" <i>Int. J. Mol. Med.</i> , 2001, 7(6):645-652.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		


Examiner Signature	/Amelia Owens/	Date Considered	02/27/2007
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/764,728		
		Filing Date	January 26, 2004		
		First Named Inventor	Q. Ping Dou		
		Group Art Unit	1614		
Sheet	1	of	1	Examiner Name	
				Attorney Docket Number	USF-T195XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AO	R1	ADAMS, J. <i>et al.</i> "Proteasome inhibitors: A novel class of potent and effective antitumor agents" <i>Cancer Res.</i> , 1999, 59:2615-2622.	
AO	R2	ALMOND, J.B. and G.M. COHEN "The proteasome: a novel target for cancer chemotherapy" <i>Leukemia</i> , 2002, 16:433-443.	
AO	R3	DOU, Q.P. <i>et al.</i> "Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy" <i>Prog. Cell Cycle Res.</i> , 2003, 5:441-446.	
AO	R4	DOU, Q.P. and B. LI "Proteasome inhibitors as potential novel anticancer agents" <i>Drug Resis. Updates</i> , 1999, 2:215-223.	
AO	R5	KAZI, A. <i>et al.</i> "Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein" <i>Biochem. Pharm.</i> , 2003, 66:965-976.	
AO	R6	KAZI, A. <i>et al.</i> "A natural <i>musaceae</i> plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells" <i>Inter. J. Mol. Med.</i> , 2003, 12:879-887.	
AO	R7	KISSELEV, A. and A.L. GOLDBERG "Proteasome inhibitors: from research tools to drug candidates" <i>Chem. & Biol.</i> , 2001, 8:739-758.	
AO	R8	LI, B. and Q.P. DOU "Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression" <i>PNAS</i> , 2000, 97(8):3850-3855.	
AO	R9	NAM, S. <i>et al.</i> "Ester bond-containing tea polyphenols potently inhibit proteasome activity <i>in vitro</i> and <i>in vivo</i> " <i>J. Biol. Chem.</i> , 2001, 276:13322-13330.	
AO	R10	PAGANO, M. <i>et al.</i> "Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27" <i>Science</i> , 1995, 269:682-685.	
AO	R11	VERMA, I.M. <i>et al.</i> "Rel/NF- κ B family: intimate tales of association and dissociation" <i>Genes & Devel.</i> , 1995, 9:2723-2735.	
	R12		
	R13		

Examiner Signature	/Amelia Owens/	Date Considered	02/27/2007
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.